TY - JOUR
T1 - Corrigendum to ‘Salivary gland cancer
T2 - ESMO–European Reference Network on Rare Adult Solid Cancers (EURACAN) Clinical Practice Guideline for diagnosis, treatment and follow-up’: [ESMO Open 7(6):100602, December 2022] (ESMO Open (2022) 7(6), (S2059702922002320), (10.1016/j.esmoop.2022.100602))
AU - van Herpen, C.
AU - Vander Poorten, V.
AU - Skalova, A.
AU - Terhaard, C.
AU - Maroldi, R.
AU - van Engen, A.
AU - Baujat, B.
AU - Locati, L. D.
AU - Jensen, A. D.
AU - Smeele, L.
AU - Hardillo, J.
AU - Costes Martineau, V.
AU - Trama, A.
AU - Kinloch, E.
AU - Even, C.
AU - ESMO Guidelines Committee
AU - Machiels, J. P.
N1 - Publisher Copyright: © 2023 The Author(s)
PY - 2023/10/1
Y1 - 2023/10/1
N2 - The authors regret that there were errors in the text and published figures. The authors would like to apologise for any inconvenience caused. The corrections are as follows: On page 3, in Figure 1, an option is added after “cT1-T2, N0”: • High gradecThis option then connects with the box containing “CT of the chest FDG–PET–CT [III, A]”. On page 3, in Figure 1 and the figure footnote, a new footnote ‘b’ is added to the following boxes: • cT3-T4, N0 or AdCC any stageb• cT1-T2, N0bb bFDG–PET–CT is recommended for treatment planning in lymph node-positive or high-grade SGC; otherwise, CT of the chest can suffice.On page 3, in Figure 1 and the figure footnote, a new footnote ‘c’ is added to the following box: • High gradecc cDefinition of high-grade tumours is described in Section 1 of the Supplementary Material, available at https://doi.org/10.1016/j.esmoop.2022.100602. On page 3: • FDG–PET–CT is recommended in high-grade SGC for the detection of distant metastases [III, A].is replaced with: • FDG–PET–CT is recommended in high-grade or lymph-node positive SGC for the detection of distant metastases [III, A]. On page 5, in Figure 2: • No high-risk factors: RT to primary [IV, A]is replaced with: • High-risk factors: RT to primary [IV, A]On page 5, in Figure 2: • RT to neckis replaced with: • RT to level I-V for pN+ [IV, A]and an arrow is added between the box containing “END II-IV (I and V on indication) [IV, B] and the box containing “pN0”. On page 5, in Figure 2: • pN+ and no high-risk factors: RT to level I-V [IV, A]is replaced with an arrow to the box containing “RT to level I-V for pN+ [IV, A]”. On page 6, in Figure 3, an additional option is added following “Open approach [IV, A]” and “Selected transoral/endoscopic/robotic [V, A]”: • High-risk factors: RT to primary [IV, A] On page 8, in Figure 4, an additional option is added following “Resection of submandibular gland and level Ib [IV, B]”: • pN+with arrows connecting to “Comprehensive ND I-V including the primary [IV, A]” and “RT to level I-V [IV, A]”. On page 8, in Figure 4: • pN0: No additional treatmentis replaced with: • pN0with an arrow connecting to: • High-risk factors: RT to primary [IV, A] On page 9, before the recommendations of “Surgical management of the primary: submandibular gland cancer” the following text is added: • Surgical management of the primary: minor SGC and cancer of the sublingual gland o Depending on the anatomical site of origin, a classical open approach [IV, A] or endoscopic, transoral or combined transoral-endoscopic resection [V, A] are recommended in selected patients, with the aim of achieving free margins. On page 10: • In case of R/M disease, systemic treatment is challenging but can be urgent, depending on tumour subtype and behaviour. For all types of SGC with distant metastases (71% of patients will present or develop R/M disease), median OS is 15 months and 1-, 3- and 5-year OS rates are 54.5%, 28.4% and 14.8%, respectively.is replaced with: • In case of R/M disease, systemic treatment is challenging but can be urgent, depending on tumour subtype and behaviour. For all types of SGC with distant metastases (up to 60% of patients will present or develop R/M disease), median OS is 15 months and 1-, 3- and 5-year OS rates are 54.5%, 28.4% and 14.8%, respectively.
AB - The authors regret that there were errors in the text and published figures. The authors would like to apologise for any inconvenience caused. The corrections are as follows: On page 3, in Figure 1, an option is added after “cT1-T2, N0”: • High gradecThis option then connects with the box containing “CT of the chest FDG–PET–CT [III, A]”. On page 3, in Figure 1 and the figure footnote, a new footnote ‘b’ is added to the following boxes: • cT3-T4, N0 or AdCC any stageb• cT1-T2, N0bb bFDG–PET–CT is recommended for treatment planning in lymph node-positive or high-grade SGC; otherwise, CT of the chest can suffice.On page 3, in Figure 1 and the figure footnote, a new footnote ‘c’ is added to the following box: • High gradecc cDefinition of high-grade tumours is described in Section 1 of the Supplementary Material, available at https://doi.org/10.1016/j.esmoop.2022.100602. On page 3: • FDG–PET–CT is recommended in high-grade SGC for the detection of distant metastases [III, A].is replaced with: • FDG–PET–CT is recommended in high-grade or lymph-node positive SGC for the detection of distant metastases [III, A]. On page 5, in Figure 2: • No high-risk factors: RT to primary [IV, A]is replaced with: • High-risk factors: RT to primary [IV, A]On page 5, in Figure 2: • RT to neckis replaced with: • RT to level I-V for pN+ [IV, A]and an arrow is added between the box containing “END II-IV (I and V on indication) [IV, B] and the box containing “pN0”. On page 5, in Figure 2: • pN+ and no high-risk factors: RT to level I-V [IV, A]is replaced with an arrow to the box containing “RT to level I-V for pN+ [IV, A]”. On page 6, in Figure 3, an additional option is added following “Open approach [IV, A]” and “Selected transoral/endoscopic/robotic [V, A]”: • High-risk factors: RT to primary [IV, A] On page 8, in Figure 4, an additional option is added following “Resection of submandibular gland and level Ib [IV, B]”: • pN+with arrows connecting to “Comprehensive ND I-V including the primary [IV, A]” and “RT to level I-V [IV, A]”. On page 8, in Figure 4: • pN0: No additional treatmentis replaced with: • pN0with an arrow connecting to: • High-risk factors: RT to primary [IV, A] On page 9, before the recommendations of “Surgical management of the primary: submandibular gland cancer” the following text is added: • Surgical management of the primary: minor SGC and cancer of the sublingual gland o Depending on the anatomical site of origin, a classical open approach [IV, A] or endoscopic, transoral or combined transoral-endoscopic resection [V, A] are recommended in selected patients, with the aim of achieving free margins. On page 10: • In case of R/M disease, systemic treatment is challenging but can be urgent, depending on tumour subtype and behaviour. For all types of SGC with distant metastases (71% of patients will present or develop R/M disease), median OS is 15 months and 1-, 3- and 5-year OS rates are 54.5%, 28.4% and 14.8%, respectively.is replaced with: • In case of R/M disease, systemic treatment is challenging but can be urgent, depending on tumour subtype and behaviour. For all types of SGC with distant metastases (up to 60% of patients will present or develop R/M disease), median OS is 15 months and 1-, 3- and 5-year OS rates are 54.5%, 28.4% and 14.8%, respectively.
UR - http://www.scopus.com/inward/record.url?scp=85169479433&partnerID=8YFLogxK
U2 - https://doi.org/10.1016/j.esmoop.2023.101630
DO - https://doi.org/10.1016/j.esmoop.2023.101630
M3 - Comment/Letter to the editor
C2 - 37625197
SN - 2059-7029
VL - 8
JO - ESMO open
JF - ESMO open
IS - 5
M1 - 101630
ER -